Curanex Pharmaceuticals, Inc. IPO
Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) – Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the closing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering was conducted on a firm commitment basis. The Company’s shares of common stock began trading on the Nasdaq Capital Market on August 26, 2025 under the ticker symbol “CURX.”
The Crone Law Group, P.C., led by partners Eleanor Osmanoff and Joe Laxague, acted as the U.S. counsel to the Company.
The Company has granted the underwriters an option, exercisable within 45 days from the close of the Offering, to purchase up to 562,500 additional shares of common stock at the public offering price, less underwriting discounts and expenses.
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability.
The Company has validated Phyto-N’s effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The primary indication is moderate to severe ulcerative colitis. The Company will advance its lead botanical drug candidate, Phyto-N, through FDA-required studies, IND submission, and into Phase I clinical trials.
About The Crone Law Group, P.C.
The Crone Law Group, P.C. is an international law firm headquartered in New York. We represent domestic and international clients in complex corporate and securities transactions. We are renowned for our expertise in the most complex securities, corporate finance matters, capital markets, initial public offerings (IPOs), uplistings, mergers and acquisitions (M&A), litigation, intellectual property and patent law, tax law, and immigration law, while providing our clients with close, personal service not available at larger, less relationship-focused firms.
Meet our team members click here
To contact The Crone Law Group info@cronelawgroup.com